To clarify the basis of the new prevention guidelines, The Lancet recently published an editorial comment by Donald M. Lloyd-Jones, MD ScM, David Goff, MD PhD, and Neil J. Stone, MD, FACC, who responded to an editorial by Paul Ridker, MD, MPH, FACC and Nancy Cook, MD.
They note that “importantly, only about 31 percent of Americans aged 40—75 years without existing cardiovascular disease might be eligible for statin therapy under the new guidelines. This is remarkably similar to what would have occurred under the previous guidelines if the threshold for treatment were lowered modestly from 20 percent 10-year risk of a heart attack to 10 percent risk, well short of the threshold of proven benefit in recent trials. Further, many of these patients are likely already on statin therapy, and many would be recommended for treatment by either risk assessment approach.” Continue reading
This post was authored by Deepak L. Bhatt, MD, MPH, FACC, associate editor of CardioSource Science and Quality, Christopher P. Cannon, MD, FACC, editor of CardioSource Science and Quality and Kim A. Eagle, MD, FACC, associate editor of CardioSource Science and Quality.
Some of the hottest practice-changing trials have been presented at the ACC’s Annual Scientific Sessions. Late-Breaking Clinical Trials (LBCTs) were first introduced at ACC’s meeting in 2001, and since their inception, LBCTs have become one of the main reasons hundreds of scientists submit their findings each year for consideration into the ACC’s program. It is also one of the many reasons thousands of cardiovascular professionals travel far and wide to attend and hear first-hand the practice-changing research. Continue reading
As the country prepares to participate in the tradition of giving thanks, spending time with loved ones near and far, and enjoying turkey dinners, I want to express my gratitude for all of the ACC’s leaders, members, staff, partners, and all who are involved in sharing the College’s mission of transforming cardiovascular care and improving heart health.
By now most of you have probably heard that the College’s old headquarters building in Bethesda, MD – the original Heart House – was finally sold. As approved by the Board of Trustees, the property was sold to Streetscape Properties, LLC , a real estate developer. The property has always been zoned for single family homes and ACC operated as a non-profit organization under a Special Exception granted by the county. Streetscape will utilize the property for which it was zoned and build single family homes. Continue reading
Sam, the counter man at High Performance Auto in my home town, was legendary among us kids. He was gray and grizzled, yet full of youthful enthusiasm, able to tell the make and model of a car by the carburetor footprint or head gasket shape, and was always willing to help tweak just a bit more horsepower out of an overwrought engine. His genius for each part was unique.
Growing up in the ‘60s, that last heyday of “muscle cars,” such things were important. Each of us had our favorite; some were Chevy people enamored with the Camero, others Mopar junkies, their fix a Road Runner or Challenger, and some, like me, Ford fanatics, my ride of choice a 1966 Mustang. Continue reading
This post was authored by Marie Boyle Reinman, RN, director of heart and vascular services and critical care nursing at Beaumont Hospital in Grosse Pointe, MI; and Sarine John-Rosman, MD, FACC.
With heart failure (HF) readmissions for Medicare patients in southeast Michigan surpassing the national average of 24.4 percent in 2010, the ACC’s Michigan Chapter decided to take the problem head on by joining together with Michigan’s Quality Improvement Organization, MPRO, and the Great Detroit Area Health Council to form the Southeast Michigan “See You in 7” Hospital Collaborative. The goal: increase the number of follow-up appointments scheduled within seven days of discharge by implementing lessons learned from ACC’s Hospital to Home (H2H) early follow-up challenge, “See You in 7.” This post is part of a series on H2H at the local level.
Beaumont Grosse Pointe is a 280 bed community hospital and it was felt we might have an easier time getting our arms around the HF readmission issue due to our size. We chose the metrics we thought would have the biggest impact: Continue reading
The ACC’s presidential team and several ACC staff were busy at the American Heart Association (AHA) Scientific Sessions 2013 in Dallas, TX, this past week.
The meeting included the latest cardiovascular science with late-breaking clinical trials like TOPCAT, which looked at the treatment of preserved cardiac function heart failure with an aldosterone antagonist, and CORAL, which looked at renal artery stenting in preventing cardiovascular and renal events. Check out CardioSource.org for complete meeting coverage.
The presidential team and I also had the opportunity to meet with many of our international colleagues from all over the globe, including China, Russia, the Caribbean, Egypt, Mexico, Brazil, Japan, and several other countries. Continue reading
A recent Bloomberg headline screamed “doctors use euphemism for 2.4 billion in needless stents,” a reference to the appropriate use criteria language change from “inappropriate” to “rarely appropriate.” If only it were that simple.
The author, like most non-medical novitiate, wishes to perceive medicine as crisp, clean and unambiguous, governed by a set of inviolate rules to which adherence should be absolute and deviation considered detrimental.
The painful truth is that the medical decision making process is messy, its subtlety difficult to articulate, and in the vast majority of cases a decision’s direction is tinted by the life experiences of the patient and their family, the medical version of “beauty is in the eye of the beholder.” And so it is with “inappropriate” and “rarely appropriate,” categories simply reflecting that sometimes a patient’s decisions just go against the rules, and sometimes the circumstances are simply extraordinary. Continue reading
A story in today’s New York Times raises concerns about the new AHA/ACC Guideline for the Assessment of Cardiovascular Risk which offers a new and improved approach to estimating a patient’s 10-year risk of developing atherosclerotic cardiovascular disease (ASCVD).
With 1 in 3 Americans dying of cardiovascular diseases and stroke, there is a critical need to improve prevention. For this reason, the ACC and AHA stand behind the new guideline and related tools, the process in which they were created and the degree to which they were approved by the panel of experts. Continue reading
This post was authored by Kim Allan Williams, Sr., MD, FACC, vice president of the ACC.
It is estimated that about 78 million U.S. adults have high blood pressure. With no warning signs and no symptoms, it is often called “the silent killer.”
According to data from the National Health and Nutrition Evaluation Survey from 2007-2010, 81.5 percent of those with hypertension were aware they had it, and 79.9 percent were being treated, but only 52.5 percent were under control, with significant variation across different patient subgroups. Continue reading
This post was authored by Shal Jacobovitz, CEO of the ACC.
Last week I had the privilege of being part of a keynote discussion at a U.S. News “Hospital of Tomorrow” event around the topic of “Working Together Toward Solutions.”
Up until recently, the U.S. health care system has been largely defined by individual constituencies, working separately and rarely teaming up. However, with the advent of health reform, collaboration among diverse stakeholders, such as payers, hospitals, medical specialty societies, consumer companies, industry, patients and others, is increasingly front and center. Continue reading